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Adolescence is a period of vulnerability to substance use disorders (SUDs). Epidemiological studies
indicate that about 23% of Brazilian adolescents use drugs, with alcohol being the most widely
consumed substance. The etiology of SUDs is complex, influenced by an interaction of genetic risk,
individual development, environmental factors, context of use, and substance used. Clinicians should
consider diagnostic criteria and be aware of behavioral changes that may indicate drug use and its
consequences in various aspects of adolescent life. Identification and treatment of comorbid
conditions is critical to the management of SUDs in this age group. Interventions should restrict
access to drugs and facilitate prompt recognition of initial use, preventing progression to serious
patterns of abuse or dependence. Intervention should be broad, including academic and occupational
activities as well as social relationships and leisure, which are critical to the reestablishment of normal
adolescent development.
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Introduction
Adolescence is a period of identity formation in which new
activities, including social, emotional, and sexual relation-
ships, are experienced. Legal and illicit substances are
frequently used during adolescence1: approximately 72%
of U.S. teens2 and 65.2% of students in Brazil3 reported
having tried alcohol. Alcohol and drug use tends to
increase in late adolescence and early adulthood, but
decreases as individuals age (tobacco use is an excep-
tion, tending to remain in adulthood), a phenomenon
called maturing out.4 However, substance use may lead
to academic issues and move adolescents away from
activities important to their cognitive and emotional
development - for example, it hinders vocational choices
and interferes with the development of skills to deal with
emotions.5 According to the World Health Organization
(WHO),6 1.7 million teenagers worldwide lose their lives
every year, mostly because of traffic accidents, suicide
and homicide, often associated with the consumption of
alcohol or other drugs. Investing in prevention is an
essential aspect of delaying initial contact with alcohol
and drugs, since early experimentation is associated with
higher odds of shifting to regular use and dependence.5
The objective of the present article is to provide data on
the prevalence of general substance use in adolescence,
assess the risk and protective factors involved in the
etiology of substance use disorder (SUD) in this population,
and address its clinical aspects, diagnosis, prevention, and
treatment.
Epidemiology
According to the United Nations Office on Drugs and
Crime (UNODC),7 it is estimated that between 153 and
300 million people aged 15 to 64 years used illicit
substances at least once in 2010, which corresponds to
3.4 to 6.6% of the world population in this age group. The
UNODC also estimates that 12% of this population (15.5
to 38.6 million) is composed of problematic drug users,
including individuals with addiction and other SUDs.
Furthermore, illicit drug use accounted for roughly
99,000 to 253,000 deaths worldwide in 2010, which
represents 0.5 to 1.3% of all causes of death. These
numbers increase further if legal drugs, especially alcohol
and tobacco, are also taken into account. WHO estimates
that 2.5 million people die annually because of harmful
use of alcohol, whereas 5.4 million deaths are caused by
tobacco use.8
In the United States, the use and abuse of alcohol
occurs on average at 14 years of age, and the use of
other drugs, at age 15. In late adolescence, 78.2% of
adolescents have consumed alcohol and 42.5% have
already used at least one illicit drug.9,10 In a study
involving elementary and high school students from 27
Brazilian state capitals, the prevalence of drug use was
22.5%. The proportion of users increases with age, but it
is worrisome that 12.7% of students aged 10 to 12 years
have already used some psychoactive substance at least
once in their lives.3 Table 1 compares the findings of
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epidemiological research conducted in Brazil and other
countries, illustrating the influence of socioeconomic and
cultural differences on drug use.
Brazilian data are consistent with the international
literature and rank SUD as the fourth most prevalent
mental health problem among adolescents (11.4%),14
with alcohol consumption as the leading cause.15
Involvement with drugs occurs in stages, beginning with
experimental use, usually in a social context, moving to
casual use and a gradual intensification in frequency
(recreational use, regular use), increasing the risk of
developing SUD (abuse and addiction).4 Drug initiation
and the sequence of drug use progression often varies on
a case-by-case basis. Substances that are legal for adult
consumption, such as alcohol and tobacco, tend to
precede and increase the risk of using illegal drugs.16
Heavy use of alcohol is associated with use of other
drugs, such as solvents (26.5%), cannabis (17.3%),
tobacco (14.2%), anxiolytics (10.5%), amphetamines
(8.1%), and cocaine (7.2%).17 Early use of alcohol is
associated not only with drug abuse, but also with
delinquency, antisocial behavior in adulthood, and school
failure.18 Moreover, the first use of a heavier drug often
occurs along with alcohol, tobacco, or cannabis.19
Alcohol is the most commonly used substance by youth
worldwide, and initiation of alcohol consumption is
occurring at increasingly early ages.20 In 2004, the
average age at first drug use among Brazilian students
was 12.5 years for alcohol, 12.8 for tobacco, 13.9 for
cannabis, and 14.4 for cocaine. This information is
important to the implementation of preventive strategies,
which should begin around the age of 10 and focus on
alcohol and tobacco, with the goal of delaying first
exposure to drugs.21
In Brazil, alcohol is the most commonly consumed and
abused drug during the life course, followed by tobacco
and cannabis.22 Although 66% of teenagers surveyed
have declared themselves teetotal, 13% had a pattern of
heavy alcohol consumption, 10% consumed alcohol 1-3
times per month, and 5% reported binge drinking or
drinking to the point of intoxication. Another alarming fact
is that among adolescent binge drinkers, 45% binge at
least once a month and 18% once a week or more. In
short, a minority of teenagers exhibit a high frequency
and intensity of alcohol use. The United States has the
highest rates of binge drinking, drug use, and violent
deaths in the Western world,23 and binge drinking
accounts for 90% of all alcohol consumed by people
under 21 in the country.24 Around 37.9% of U.S. high
school girls use alcohol, of whom 54.6% reported binge
drinking (19.8% of all students).25 In Europe, the average
rate of lifetime alcohol use is 88%; England, where the
frequency of binge drinking in high school girls was 54%,
leads the European ranking.26
Use of alcohol and tobacco during youth is a predictor
of their use in adulthood and of substance-related
disorders.27 In a systematic review of the literature on
the use of alcohol and tobacco by adolescents aged 10 to
19 years, Barbosa Filho et al. found that the prevalence of
current tobacco use (at the time of survey or in the
preceding month) ranged from 2.4 to 22.0%, averaging
9.3%.28 In a study about smoking among adolescents
aged 13 to 15 years in the Brazilian cities of Florianopolis,
Curitiba, and Porto Alegre,29 the authors found a
predominance of smoking behavior in girls compared to
boys. This finding is similar to those reported in other
countries surveyed by WHO, except in Europe.30
Although the risk of onset of tobacco use by adolescents
is higher when parents are smokers,31 there are other
family factors associated, such as parenting practices of
low acceptance and low behavioral control of children.32
In addition to the implications of tobacco use on
adolescent health, it bears noting that concomitant use
of tobacco and cannabis is common.33
Cannabis is the most widely used illicit substance
worldwide, with 119 million to 224 million users.7 A 2005
survey found that cannabis was the illicit drug with the
highest rate of lifetime use among Brazilian adolescents
aged 12 to 17 (4.1%), followed by solvents (3.4%).22
Among students of public schools, the proportion of
cannabis use was even greater (5.9%), but solvent use
was most common overall (15.5%). Socioeconomic and
cultural factors associated with this low-income popula-
tion may explain the higher proportion of solvent users, as
solvent consumption is higher in underdeveloped and
developing countries.34 It is noteworthy that the preva-
lence of self-reported drug use may be underestimated
because of the difficulty of measuring illegal behaviors.
The use of energy drinks has also been measured in
recent epidemiological surveys. These drinks are widely
consumed in combination with alcohol to increase their
excitatory effect.35 Among Brazilian students, the lifetime
Table 1 Lifetime prevalence of substance use among students (%)
Substances Brazil3 Chile11 Venezuela12 Paraguay12
United
Kingdom13 Italy13 Greece13 U.S.2
Alcohol 65.2 78.6 65.5 66.9 91.0 82.0 91.0 72.7
Tobacco 24.9 75.0 31.8 37.3 58.0 64.0 50.0 47.1
Inhalants 15.5 7.9 2.7 0.7 12.0 6.0 15.0 11.1
Cannabis 5.9 21.6 1.0 4.3 38.0 27.0 6.0 42.3
Cocaine 2.0 3.7 1.0 1.6 3.0 3.5 1.0 8.5
Anxiolytics 4.1 9.1 15.8 15.0 2.0 6.0 4.0 10.3
Amphetamine 3.7 5.8 6.4 5.9 8.0 2.6 1.0 *
Opioids 0.3 1.3 * * * * 2.0 1.4
Hallucinogens 0.6 1.9 * * * * * 8.3
Illicit drugs 19.4 17.1 * * 47.0 35.0 9.0 48.2
* Not available.
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prevalence of energy drink consumption (combined or not
with alcohol) was 12%.3 In the United States, about 6% of
adolescents and young adults use energy drinks daily.36
Use of anabolic steroids has also increased, reaching
6.6% of adolescent males in Brazilian high schools; the
risk of use is two- to threefold higher among boys
compared with girls,37 and is most likely among spon-
sored athletes. The average age at first use is 14 years,
but use before the age of 10 has been reported.38
Rates of cocaine and crack use among Brazilian
adolescents (2.0 and 0.7% respectively) are lower than
those of alcohol, tobacco, inhalants, and cannabis. The
proportion of American adolescents who use cocaine is
much higher (8.5%); however, only 0.1% of adolescents
use crack in the country.2,39 The severity of psychiatric,
family, and social problems is far greater among users of
crack and cocaine: higher rates of antisocial personality
disorder in adulthood (25%) and occupational, family and
legal problems, including violent activities such as theft
and robbery (23%)and threats and assault (32%), have
been reported.40
The environment and life context exert great influence
on substance use. In a survey of Brazilian children and
adolescents living on the streets, 47.7% used drugs
heavily or frequently, and 74.2% used multiple drugs.41
Street children and adolescents without family bonds and
not attending school (25.7% of the sample) were at even
greater risk, with86.4% using drugs heavily or frequently.
Etiology and risk factors
The etiology of drug use is multifactorial, and identifying
its various determinant factors is a complex task. For
didactic purposes, this article examines some subdivi-
sions of etiologic factors, namely neurobiological aspects
and social, genetic, and psychiatric comorbidities.
However, this division into topics is artificial, because
the causative factors of drug use are interrelated, each
factor modifying the clinical expression of others.42-44 The
genetic aspect is triggered by environmental factors
(epigenetics) or behavioral factors in response to
environmental aspects. Knowledge of these factors is
necessary to identify possible targets for intervention.
Adolescent neurobiology and risk of drug experimentation
The reward system (RS) is the brain structure responsible
for feelings of pleasure that can lead to repeat behaviors.
This system is triggered by activities related to survival,
such as sexual desire and feeding, but also by drugs of
abuse. The main pathways of the RS are the mesolimbic
and mesocortical pathways, and numerous projections of
the amygdala, prefrontal cortex and hippocampus reach
the nucleus accumbens, which plays an important role in
regulating emotion, motivation, and cognition. The main
neurotransmitter released in this system is dopamine, the
repeated release of which leads to learning the behavior
of obtaining and using the drug. When consumption
persists, a sensitization phenomenon occurs in mesolim-
bic pathways by synaptic plasticity, leading to a more
intense and persistent consumption.45
Recent research has shown that the brain undergoes
structural and functional changes during its development.
The brain regions responsible for the so-called social
brain are the last to develop46 and various structures that
are part of the RS are still developing in adolescence.
From the beginning to the end of adolescence, the
nucleus accumbens undergoes several changes and
about 30% of its dopamine receptors are lost. This
change may be associated with greater feelings of
boredom and attempts to search for stronger sensations
in this age group. In this context, drugs can fulfill a
biological need for dopamine; hence, the high risk of drug
use during this period.47
During adolescence, the frontal cortex (responsible for
working memory, impulse control, and abstract reason-
ing), loses gray matter while white matter increases.48,49
Making decisions with an emotional component is a
function of the orbitofrontal cortex, one of the last regions
to mature, and its operational deficit is associated with
drug use in early adolescence.50 The predominant
pattern of novelty-seeking in childhood is a risk factor
for drug use in adolescence.51,52
Adolescents have full capacity for abstract thinking;
they have many ideas and the energy to put these into
practice. However, their ability to assess risks, conse-
quences and temporally organize causal relations is still
immature, especially when influenced by emotions and by
the desire for immediate gratification. These character-
istics make teenagers more vulnerable to drug experi-
mentation, especially if access to drugs is easy and if
their environment accepts this behavior. Therefore, these
aspects related to neurocognitive and emotional devel-
opment in this age group should be considered when
assessing the risk and protective factors to which
teenagers are exposed.53,54
Social factors
Social factors are important determinants of the risk of
drug experimentation, regular drug use, and addiction in
adolescence. Interestingly, protective factors are less
often investigated. Weiland et al. found that individuals
with greater potential for resilience (defined as a
combination of factors that promote conditions to face
and overcome problems and adversities), indirectly
measured through neuropsychological findings corrobo-
rated by neuroimaging, had lower levels of substance
use.55 Another study found that high scores on scales of
resilience were associated with a more significant
protective factor in adolescent females than in males. In
turn, risk factors, such as family dysfunction or being
friends with offenders, were more decisive in the overall
intensity of drug use in males than in females.56 Other
studies have found that religiosity57,58 and effective
parental monitoring59-62 are important protective factors.
Risk factors for drug experimentation include: drug use
by parents and friends63; unsatisfactory academic per-
formance64; bad relationship with parents65; low self-
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esteem66; depressive symptoms67; history of stressful
events68; and early use of alcohol and cigarettes.69 The
onset of alcohol use has a strong positive correlation with
family influence, since studies show that when teens have
parents who also use alcohol, experimentation with legal
substances in the family context is frequent.63,70
Factors related to adolescent personality traits, such as
a high tendency to seek novelty and low avoidance of
harm, as well as high reward dependence,71 are
associated with increased risk of experimental substance
use. The main predictors of progression to the next
stages of consumption are the intensity of use at an
earlier stage and the influence of environmental factors -
drug availability, cost, and cultural influences, from the
media and - especially - peer influence.16 In turn, drug
use at one stage does not imply progression to the next,
but generally requires involvement with drugs at the
previous stage. Differences, especially regarding the first
drug consumed and the progression to the next stages,
once again reflect the influence of the previously
mentioned environmental factors - mainly peer influence.
Ease of access to drugs and the opportunity to use them
are important factors in the initiation of use. A study of
cannabis, cocaine, hallucinogens, and heroin demon-
strated a 1-year interval between the first opportunity to
use and the first use.72 The rates of use opportunities
were comparable to the prevalence of drug use, and
there was no difference between genders in use after the
first opportunity to do so. However, females had fewer
opportunities to use drugs, and this applied to all of the
drugs studied.
In terms of continuous use and progression to other
drugs, adolescents’ internal factors - behavior, individual
resilience, presence of psychiatric comorbidities, low self-
esteem, difficulties in implementing and defining their
social identity - are important influences.72 Continuous
use of drugs is also related to environmental factors, not
only because of the previously mentioned issues of peer
influence and family, but also through conditioning
processes involved in addiction, related to the develop-
ment of tolerance, withdrawal, relapse, and overdose.73
In this sense, some environmental characteristics (such
as place of use, partners, time and proper handling of the
drug) elicit compensatory effects in the body. The effect is
felt, for example, as an intense increase in willingness to
use when in that context (craving) and as a progressive
decrease of the sensations produced by the drug,
requiring greater and greater amounts (tolerance).74
Genetic factors
Genetic factors have been widely studied and play an
especially important role in the use of alcohol, cigarettes,
and illicit drugs in adulthood.34,42,75 Heredity for abuse
and addiction is complex, indicating the involvement of
genetic influences that may be more relevant than
environmental factors, especially for heavy use.76 Twin
studies have shown that genetic factors are more
importantly associated with substance addiction in girls
than in boys.77 A systematic review of twin studies
indicates a concordance of about 50% for experimenta-
tion and frequent use of cannabis in teens.76 The same
proportion of 50% was found in review studies that
evaluated the heritability of alcohol addiction.78 However,
children of alcoholics appear to have four times the risk of
developing alcoholism, even if raised by non-alcoholics.79
Psychiatric comorbidities
A study of 1,285 subjects aged 9 to 18 years found that
the presence of anxiety disorders, mood disorders,
oppositional defiant disorder (ODD), and conduct dis-
order (CD) was related to later use of alcohol, cigarettes,
and illicit drugs.80 Another study of 497 attention-deficit/
hyperactivity disorder (ADHD) patients estimated a
relative risk of 1.47 for drug use in adolescence after a
follow-up of 10 years. In the same study, patients with
comorbid ODD or CD had a relative risk of 2.74 and 2.21
respectively.81 However, a meta-analysis of 1,000 indivi-
duals found that ADHD alone might not be an indepen-
dent risk factor for substance use (RR = 1.35 [0.90-2.03])
when CD and ODD are excluded.82
Panic disorder predicts alcohol use in adolescence and
adulthood, while social phobia is associated with alcohol
and cannabis.83,84 Bipolar disorder and depression are
important risk factors, and they often precede substance
use in childhood and adolescence.85,86
Therefore, the etiology of substance abuse is complex
and multifactorial. Both genetic and environmental factors
contribute to the development of SUDs. Adolescence is a
period of higher odds of developing high-risk behaviors -
including substance use - because the neurocognitive
systems responsible for risk assessment, impulsivity
control, and social interaction are still under development.
The risk of developing SUD increases when comorbidities
are present. Generally, the greater the number of risk
factors present, the greater the risk of developing more
severe addiction.87-90 Hence, the importance of investing
in prevention programs and early diagnosis.
Diagnostic criteria
The psychiatric nosology of the two main SUDs, abuse
and dependence, evolved largely because of epidemio-
logical studies of alcohol-dependent adults. Table 2
presents the current diagnostic criteria according to the
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition, text revision. However, in adolescence,
abuse and dependence can be a one-dimensional
construct.91 Therefore, the categories shown in the table
have limitations in the assessment of adolescents.
Given the peculiar characteristics of adolescence, the
imprecision of diagnostic criteria can lead to increasing
levels of severity of substance use. Some authors
propose to evaluate the levels of use over a spectrum,
ranging from experimentation to addiction.93 Cohen &
Estroff point out that diagnosis of substance abuse in
young people depends more on clinical sensitivity than on
set criteria.94 In an attempt to improve clinical perception,
Nowinski suggests five stages for substance use pro-
GM Lopes et al.S54
Rev Bras Psiquiatr. 2013;35(Suppl 1)
gression in adolescents: 1) experimental: use is moti-
vated by curiosity and/or risk-taking; 2) social: use is
related to social events; 3) instrumental: use has the
purpose of manipulating emotions and behaviors, such as
seeking pleasure or dealing with stress or dysphoria; 4)
habitual: accommodation - the user’s lifestyle becomes
centered on use as a means of coping and recreation,
and former interests are abandoned; 5) compulsive
disorder: total preoccupation with use; all activities
revolve around the use of drugs, and global functioning
deteriorates.93
In short, clinicians should be alert not only to diagnostic
criteria, but also to changes in behavior that may indicate
the use of drugs, as well as to their consequences. Thus,
preventive measures and interventions can be imple-
mented, minimizing contact with drugs and, in the case of
use, preventing the progression of consumption.
Clinical assessment
The following data should be collected for each sub-
stance: 1) age at first use; 2) age of progression to regular
use; 3) maximum use; 4) current use (over the past
month); and 5) last use. The DSM-IV-TR diagnostic
criteria for abuse or dependence should then be applied.
Other important information includes: triggers for eager-
ness (craving) and use, context of use (e.g., with
particular peers, at school, or before school); perception
about motivation for use, and positive and negative
consequences of using, as well as the current motiva-
tional stage and the goals of treatment.95 All these data
are essential for the assessment of SUD severity and
planning of necessary therapeutic interventions. It is
worth stressing that a teenager who reports regular use of
any psychoactive substance should be treated with the
aim of preventing the progression of use.
Often, in adolescence, there is a normal stage of
substance experimentation; however, in susceptible
individuals - especially in adolescence, in which the
central nervous system (CNS) is still in development - this
experimentation carries the risk of major neuropsychiatric
consequences. Intoxication usually manifests itself
through changes in mood, cognition, and behavior.
Mood can range from euphoric to depressed, with suicidal
ideation or suicidal acts. Patients may experience periods
of anxiety or panic attacks, paranoia, or acute psychosis.
Changes in cognition include poor concentration,
decreased attention, and apparent changes in perception
or thinking (e.g., delusions). Behavioral manifestations
include lethargy, hyperactivity, agitation, disinhibition,
drowsiness, hypervigilance,96 and changes in sleep and
appetite.97 Most symptoms indicative of problematic
substance use are related to psychosocial and academic
function (Table 3).
Some physical characteristics suggestive of SUDs
include unexplained weight loss, intense malaise, hyper-
tension, nasal irritation, conjunctival irritation, hoarse-
ness, chronic cough, hemoptysis, chest discomfort,
wheezing, scratch marks, needle marks, blank stares,
excessive acne, testicular atrophy,97 odor of cannabis or
other substance on clothing, and excessive use of
mouthwash and aftershave/perfume to mask the odor of
alcohol or drugs.98
The neurological consequences of psychoactive sub-
stance use vary according to the quantity, duration of use,
and type of substance used (Table 4). Prolonged
cannabis use can result in cognitive deficits,97 including
impaired integration of complex information in attention
and memory.99 Cognitive impairment is also seen in
cocaine100 and inhalant abuse in the long term.101
Seizures may occur after using cocaine and high doses
of stimulants, and chronic use of these substances is also
associated with the development of tremors.97
Adolescents rarely exhibit physical signs of withdrawal
from alcohol and other sedative-hypnotics. When these
do occur, they may experience tremors in the extremities.
The occurrence of seizures indicates severe withdrawal
syndrome, with risk of developing delirium tremens, but in
adolescents this is often associated with other clinical
problems (e.g., traumatic brain injury and metabolic
Table 2 Diagnostic criteria for substance abuse and
dependence (adapted from DSM-IV-TR)92
Criteria for substance abuse (1 of 4 criteria in 1 year)
- Recurrent use of the substance(s), resulting in failure to fulfill
most obligations
- Recurrent use of the substance(s) in situations where they
pose a hazard to physical integrity
- Recurrent substance-related legal problems
- Continued use of the substance(s) despite persistent social
problems due to its/their use
Criteria for substance dependence (3 of 7 criteria in 1 year)
- Tolerance*
- Withdrawal*
- Use in larger amounts and/or over a longer period
- Unsuccessful efforts to cut down or control use
- Great deal of time spent in activities necessary to obtain the
substance(s) or recover from its effects
- Important social, occupational, or recreational activities are
no longer carried out because of the use
- Continuous use of the substance(s), despite knowledge of
medical or psychological problems due to its/their use
* With physiological dependence.
Table 3 Academic and psychosocial indicators of substance
use97
Academic
Impaired attention and judgment
Frequent absences and tardiness
Dropout
Conflict with teachers






Conflict with teachers and other authorities
Poor hygiene
Drug-using peers
Decreased or absent interest in extracurricular activities
Social withdrawal
Frequent unexplained injuries
Identification with drug culture (clothing, music, movies)
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disorders), which must be investigated.98 Teenagers who
chronically abuse inhalants may exhibit tremors and are
at risk of developing peripheral neuropathy due to direct
damage to the nervous system.101 High doses of
stimulants can cause stroke,100 and cerebrovascular
disease may be aggravated by chronic alcohol use. The
occurrence of stroke in young patients greatly increases
the suspicion of drug abuse.97
So far, recovery from these deficits cannot be ensured.
In general, recovery depends on several factors, such as
deficit severity, sex, age, abstinence time, premorbid
cognitive level, and cognitive stimulation.106 Such defi-
cits, if untreated, can lead to progressive loss of cognitive
functions, and may not only increase the likelihood of
relapse but also hamper treatment.107 Therefore, espe-
cially in adolescents, a careful clinical and neuropsycho-
logical assessment is essential so that any existing
deficits may be identified and treated early.
Differential diagnosis and comorbidities
The Methods for the Epidemiology of Mental Disorders in
Children and Adolescents (MECA) study found the
following prevalence rates for psychiatric comorbidities
associated with SUD in adolescents for the previous 6
months: 76% for any comorbidity, 68% for any disruptive
behavior disorders, 32% for any mood disorder, and 20%
for any anxiety disorder.99 Many individuals suffer from
both SUD and other psychiatric disorders. The main
differential diagnosis should identify abuse or addiction to
one or more substances and comorbid conditions.
Externalizing disorders occur often in comorbidity with
SUD, usually secondary to drug use, and both have
common symptoms: lying, problems at school, and
involvement in illegal activities. Likewise, mood swings
are frequent and even schizophreniform states can arise
from the use of cocaine or cannabis. In turn, internalizing
disorders, especially depression and social anxiety/
phobia, may precede SUD. Drug use would occur later
as a way to relieve the characteristic symptoms of these
disorders. The association between SUDs and comorbid-
ity has direct implications for treatment.96
Laboratory tests
The use of additional tests to confirm the use of harmful
substances requires prior consent from the teenager.
Substance use monitoring has more practical relevance
when used to encourage the patient to remain abstinent,
rather than imposing drug tests as a punitive measure.
Drug testing in urine and blood can greatly aid in the
treatment of intoxication with major clinical impairment, in
which the teenager’s report is unreliable. The breath test
(breathalyzer) and saliva testing are commonly used in
the legal setting to prove intoxication, but must be
complemented by more specific tests.108
Sweat tests have been approved by the FDA to detect
cocaine, opioids, and amphetamines, but they have also
been successfully used to detect alcohol, methadone,
methamphetamine, nicotine, and phencyclidine. Although
a sweat test can detect drugs used within 1 to 4 weeks, its
use is limited by the difficulty of collecting sweat and by
the potential risk of contamination.108 Hair tests can be
used to detect drug use over a period of 4 to 6 months,
since drug metabolites are absorbed into the hair follicle 1
week after use of the substance.108 These tests have little
applicability in the clinical setting.
Blood tests can accurately detect substances within 12
to 24 hours, but they are invasive, expensive, and
restricted to recent use. They are used primarily to detect
accidents involving drugs and in medical emergencies.108
Treatment
One of the major focuses in treating adolescent drug
users is abstinence. This can be understood as a way to
achieve the ultimate goal of treatment - the resumption of
normal adolescent development. Adolescents should be
offered the chance to make a global change in their
lifestyle, giving them the opportunity to develop their skills
Table 4 Major neurological and cognitive impairments associated with drug use
Drug Cognitive and neurological deficits
Alcohol Attention, memory, learning, mental flexibility, executive function, visual-spatial organization,
psychomotor problems, impulsivity, and decision making.97,102 Tremors and convulsions may occur
during withdrawal from alcohol and other sedative-hypnotic drugs.100
Cannabis Prolonged use can result in cognitive deficits,97 including impairment in integration of complex information,
attention and memory, manual dexterity, learning, and decision making.99
Cocaine and psychostimulants Impairments in attention, concentration, memory, visual and verbal learning, verbal fluency, visual-motor
integration, executive functions and decision making.100 Seizures may occur after use of cocaine97 and
high doses of stimulants. Adolescents who chronically abuse amphetamines and other stimulants can
develop tremors.97
Solvents Impairments in attention/concentration, memory, psychomotor retardation, visual-spatial functions,
acquiring new information, executive functions, planning and manual dexterity. Peripheral neuropathy and
tremor can develop as the result of chronic inhalant use or abuse, often due to direct damage to the
nervous system.101
LSD Impairments in attention, abstraction, mental flexibility, memory, learning, executive functions, and visual-
spatial orientation.103
Ecstasy (MDMA) Impairments in complex attention, problem solving, verbal and visual memory, working memory, and
executive functions.103-105
MDMA = 3,4-methylenedioxy-N-methylamphetamine.
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in an environment free from drugs. The main points of
treatment are: 1) promoting abstinence; 2) maintaining
abstinence; 3) evaluating and treating other associated
psychiatric disorders; and 4) addressing related personal
and family factors. Adolescents should be encouraged to
participate in social and leisure activities that help then
build the required skills for appropriate cognitive and
emotional development, thus keeping them busy and
away from drugs.109
Each patient should receive individual treatment, and
physicians are responsible for defining the need for
different treatment modalities.109 Essentially, a multimodal
treatment is needed, and family involvement is critical.
Some aspects of this treatment are shown in Table 5.
The legal system is often involved in this context of
treatment, through such agencies as the Ministry of
Justice, Guardianship Councils, the Children’s Court,
services that protect teenagers at risk of death, institu-
tions for young offenders and others, especially in the
case of children and adolescents at social risk.111
Types of interventions
Non-pharmacological approaches
The existing literature rarely clarifies which therapeutic
approach was employed, reporting only the type of therapy
(group, family, individual, multidimensional) without speci-
fying the actual intervention studied.112 A 2013 meta-
analysis concluded that approaches targeted to families
and group-based interventions had the greatest influence
on response to treatment (greater effect size),113 but the
therapeutic approaches used in different studies assessed
are not clear. Brief interventions, such as motivational
interviewing for adolescents, have a small but significant
effect size, which remains over time and has the greatest
impact on reducing the use of illicit substances.114,115
Studies using new methodologies could help corroborate
clinical results, such as studies linking neuroimaging to
brain changes resulting from psychotherapeutic interven-
tions.116 Studies describing the approach and interventions
used throughout the therapeutic process in greater detail
are needed to enable proper comparative analysis of the
effectiveness of different types of available therapies.
Pharmacological treatments
Pharmacological treatments for substance abuse in
adolescents are not yet established due to a paucity of
data focusing on this age group.117 Suggested pharma-
cological treatments focus on the key symptoms of
addiction, such as decreasing cravings, replacement
therapy, and treating comorbidities. Generalizing the
results of research conducted with adults to the adoles-
cent population is a high-risk practice, since the potential
adverse effects and the therapeutic response are
different due to neurobiological differences.118
The FDA has not approved any medications for the
treatment of addiction in teenagers; therefore, treatment
of comorbidities remains the focus of psychopharmacol-
ogy in this age group.119 A recent clinical study showed
promising results with the use of N-acetylcysteine at a
dose of 1,200 mg per day for adolescent cannabis users,
increasing the odds of abstinence 2.4 times with minimal
side effects.120
Some medication classes should be avoided due to the
risk of interaction with alcohol and drugs of abuse, such
as tricyclic antidepressants (risk of cardiac arrhythmias
and anticholinergic effect, which may potentiate halluci-
natory effects); anticholinergic medications; benzodiaze-
pines (risk of decreased level of consciousness through
interaction with alcohol); and psychostimulants (risk of
cardiac arrhythmias).
Types of treatment
The ideal model of treatment for adolescents with SUD
has been widely discussed. Models range from voluntary,
involuntary, or compulsory inpatient treatment to out-
patient treatment, including community service centers,
day hospitals, and open and closed therapeutic commu-
nities.
Defining the most appropriate treatment through an
individualized assessment makes it possible to advance
treatment according to the improvement achieved with
initial interventions.121 Identification and appropriate
treatment of comorbidities is essential for the prognosis
of SUD in adolescents, as seen previously. The greater
the number of comorbidities, the worse the prognosis for
this population.68
Outpatient treatment is the first therapeutic approach,
especially when the teenager is still involved in productive
educational, recreational, or social activities. In the
outpatient setting, techniques for achieving abstinence
and for conflict resolution are discussed, and the
adolescent is encouraged to develop new activities
unrelated to drug use without being removed from his
Table 5 Aspects of the treatment of adolescents with substance use disorder*
- Psychoeducation for patients and their parents about the different aspects of the disorder, such as relapses and the need for treatment
- Improvement of communication within the family environment; motivating parents to become interested in all aspects of their children’s
development (e.g., their tastes and leisure activities) instead of focusing only on substance use
- Identification of precipitating factors of drug use and early intervention
- Improvement of self-control with cognitive-behavioral therapy
- Group therapy and social skills training can be used
- Contingencies management therapy
- Outpatient/day hospital/therapeutic communities
- Consider the need for inpatient treatment in more complex cases (aggression, suicidal behavior, risk of clinical complications, failure of
outpatient treatment)
- Medications may be used in the treatment of comorbid disorders or for key symptoms
* Adapted from Stubbe.110
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or her environment. However, youths frequently minimize
the severity of their condition and are poorly engaged in
treatment. In these cases, or when there is a hazard to
their physical integrity - either because of uncontrolled
use of drugs or involvement in illegal activities -
hospitalization becomes a necessary resource. For users
of crack or other drugs where abstinence is admittedly
difficult, inpatient treatment may be the first therapeutic
resource to be employed.122
The indications for inpatient treatment are: 1) risk of
self- or hetero-aggressive behaviors or suicidal behavior;
2) risk of developing withdrawal symptoms or other
clinical complications; 3) need for treatment of other
psychiatric comorbidities; and 4) failure of outpatient
treatment attempts.121
However, no scientific evidence proving the specific
indication of these different therapeutic modalities has
been found. In Brazil, laws that determine the involuntary
commitment of children and adolescents and the princi-
ples of the Child and Adolescent Statute may have
different interpretations, leading psychiatrists to adopt
subjective criteria when deciding on the intervention to be
conducted.123 Comparisons between surveys using
different models diverge in terms of their methodology,
which hampers effective comparative analysis.
Prevention
Whereas the main approaches for prevention of harmful
use of psychoactive substances (both legal and illegal)
involve general principles of mental health promotion,
some protective factors are listed in Table 6.
Throughout the child development process, the daily
lives of children includes not only family but also the
school environment. Therefore, preventive strategies for
mental health in childhood and adolescence need to
include training of education and health care profes-
sionals in order to be effective.125 In addition to general
approaches to prevent the harmful use of psychoactive
substances, the following preventive strategies are
needed:
- Training of mental health professionals and teachers in
primary health care (e.g., primary health care and family
health programs);
- Inclusion of courses that address mental and behavioral
disorders in the school curriculum (primary and second-
ary education);
- Implementation of media-wide campaigns to combat the
stigma against people with mental and behavioral
disorders;
- Establishment of partnerships between schools and the
primary health care network to identify cases that need to
be referred to specialized services;
- Preparation of manuals for parents and teachers, contain-
ing notes on psychiatric disorders in childhood and
adolescence;
- Creation of parent support groups that can provide
guidance for families raising children;
- Administration of interventions that are proven effective in
a school setting100 (basic principles of cognitive-beha-
vioral and motivational therapy) by facilitators (teachers,
school counselors, education specialists) to students
exhibiting personality traits associated with a high risk of
substance use (hypersensitivity to anxiety, hopelessness,
impulsiveness, novelty-seeking).51,52
Conclusions
Drug experimentation occurs in approximately 65 to 70%
of adolescents and may be part of the normal process of
youth development. However, it exposes teenagers to
various hazards, from accidents and unsafe sex to
multiple other high-risk behaviors. Adolescents with
SUD should be viewed as individuals in development,
with specific demands, which reflect on the need for
specific treatment. While treating adolescents with SUD,
proper diagnosis and treatment of comorbidities, identi-
fication of factors that lead to drug use, and active family
involvement in the therapeutic process are of the utmost
importance. In addition to abstinence of all psychoactive
substances, treatment should focus on areas such as
academic and vocational activities, vocational counsel-
ing, the environment and social relationships, as well as
leisure activities, all of which are critical to the reestablish-
ment of normal adolescent development. Strategies for
the prevention and treatment of SUDs in adolescence are
justified by the risk of serious consequences caused by
substance use at this age, such as increased risk of
developing psychiatric disorders and progression to
addiction in adulthood.
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